Insider Transactions in Q2 2024 at Allogene Therapeutics, Inc. (ALLO)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
Deborah M. Messemer Director |
SELL
Open market or private sale
|
Direct |
18,641
-10.05%
|
$37,282
$2.28 P/Share
|
|
Jun 05
2024
|
Franz B Humer Director |
BUY
Grant, award, or other acquisition
|
Direct |
61,475
+16.25%
|
-
|
|
Jun 05
2024
|
Vicki L Sato |
BUY
Grant, award, or other acquisition
|
Direct |
61,475
+27.44%
|
-
|
|
Jun 05
2024
|
Deborah M. Messemer Director |
BUY
Grant, award, or other acquisition
|
Direct |
122,950
+39.87%
|
-
|
|
May 30
2024
|
Franz B Humer Director |
SELL
Open market or private sale
|
Direct |
11,200
-4.2%
|
$22,400
$2.34 P/Share
|
|
May 16
2024
|
Arie Belldegrun Director |
BUY
Open market or private purchase
|
Indirect |
1,724,137
+50.0%
|
$3,448,274
$2.9 P/Share
|
|
May 16
2024
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Indirect |
344,828
+38.98%
|
$689,656
$2.9 P/Share
|
|
May 16
2024
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
344,828
+6.69%
|
$689,656
$2.9 P/Share
|
|
May 16
2024
|
Geoffrey M. Parker CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
344,828
+22.85%
|
$689,656
$2.9 P/Share
|
|
Apr 22
2024
|
Timothy L. Moore Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,360
-6.14%
|
$52,080
$3.47 P/Share
|